High Risk IMDRF Category III & IV Software as a Medical Device Market to Reach USD 16.9 Billion by 2036 as AI Raises Clinical Software Requirements

Rockville, Maryland, United States - September 8, 2026 - The U.S. Food and Drug Administration published draft recommendations in January 2025 covering lifecycle management and marketing submissions for artificial intelligence-enabled medical-device software, placing greater emphasis on evidence, risk management, and controlled software changes. The regulatory focus is increasingly relevant to high-risk Software as a Medical Device (SaMD), where software outputs can influence serious or critical clinical decisions.

According to Fact.MR, the global high-risk IMDRF Category III & IV Software as a Medical Device market is valued at USD 4.8 billion in 2026 and is projected to reach USD 16.9 billion by 2036, expanding at a 13.4% CAGR. The market reached USD 4.2 billion in 2025, creating an estimated absolute opportunity of USD 12.1 billion between 2026 and 2036.

Get detailed market forecasts, competitive benchmarking, and pricing trends: https://www.factmr.com/connectus/sample?flag=S&rep_id=16026

Why High-Risk SaMD Is Becoming a Regulatory Priority

Software is increasingly performing functions once associated primarily with physical medical devices. Diagnostic algorithms interpret images, monitoring platforms identify deterioration, and clinical decision-support systems provide patient-specific information that can influence treatment.

The regulatory distinction is important.

The International Medical Device Regulators Forum defines SaMD as software intended for one or more medical purposes that performs those purposes without being part of a hardware medical device. The FDA similarly recognizes standalone medical software as a distinct category requiring risk-based oversight.

For Category III and IV products, the consequences of an incorrect output can be significant. Manufacturers therefore need evidence that the software has a valid clinical association, reliable analytical performance, and appropriate clinical performance.

This changes the commercial equation. Hospitals are not simply buying software features. They are evaluating clinical evidence, cybersecurity, interoperability, version control, regulatory status, and how clinicians remain accountable for decisions.

Diagnostic Software Holds the Largest Software-Type Share

Diagnostic Software is projected to account for 42.0% of the market by software type in 2026, making it the leading category.

Diagnostic software supports the identification or characterization of disease where an incorrect or delayed result can affect treatment decisions. Its importance is particularly high in serious clinical situations where physicians need patient-specific information before deciding whether to intervene or conduct additional testing.

AI-enabled diagnostic tools are expanding this opportunity. Image interpretation, automated detection, prioritization, and quantitative analysis can process large volumes of clinical information while supporting existing specialist workflows.

The commercial requirement is evidence.

A model that performs well in a development dataset may still require additional validation across different hospitals, patient groups, imaging equipment, and clinical environments.

Medical Imaging Diagnostics Leads Application Demand

Medical Imaging Diagnostics is projected to represent 39.0% of application demand in 2026.

Medical imaging provides structured digital inputs that software can analyze for suspicious findings, anatomical changes, and clinical prioritization. This makes radiology and other imaging-heavy specialties natural environments for high-risk SaMD deployment.

For hospital buyers, integration can determine adoption speed. Software that fits existing imaging archives, reporting systems, electronic health records, and specialist workflows can reduce implementation friction.

For developers, however, integration cannot replace clinical evidence. The software's intended purpose and risk classification determine the validation and regulatory requirements.

Hospitals Represent the Largest End-User Segment

Hospitals are expected to account for 44.0% of the market in 2026, the largest end-user share.

Hospitals manage serious and critical cases and maintain the specialist infrastructure required to interpret high-risk software outputs. They also operate imaging systems, electronic health records, monitoring infrastructure, and other clinical platforms that supply data to SaMD applications.

Procurement teams increasingly examine the full software lifecycle.

They need to understand who receives an alert, how a recommendation is displayed, what evidence supports the output, how software updates are controlled, and how performance is monitored after deployment.

For AI-enabled systems, these questions become even more important because model behavior can change as algorithms are updated or retrained.

Cloud Deployment Takes the Lead

Cloud-based deployment is projected to account for 56.0% of the market in 2026.

Cloud architecture allows software providers to deliver computing capacity and controlled updates across multiple clinical locations. This is particularly useful for hospital groups operating distributed imaging, specialty-care, and monitoring networks.

The hosting model does not remove regulatory responsibility.

The medical purpose and risk associated with the software remain central regardless of whether the application operates on-premises, through a private cloud, or through a broader cloud infrastructure.

Cybersecurity, access controls, data governance, software-version traceability, and change management therefore remain part of the purchasing decision.

IMDRF Category III Accounts for the Larger Risk Share

IMDRF Category III is projected to represent 61.0% of the market by risk classification in 2026.

Category III covers software that informs clinical management in critical situations or drives clinical management in serious situations. Category IV represents the highest-risk functions, where an incorrect output can directly contribute to death or irreversible deterioration.

The broader range of Category III use cases supports its larger market share.

Category IV, however, remains strategically important because software operating in the highest-consequence clinical environments can command significant evidence, validation, and regulatory requirements.

"High-risk medical software is moving from a technology purchase to a clinical governance decision," said Shambhu Nath Jha, Principal Consultant at Fact.MR. "Providers need evidence that connects the algorithm to its intended medical purpose, while manufacturers must control updates, cybersecurity and performance throughout the product lifecycle."

United States Leads Country Growth

The United States is forecast to expand at a 14.6% CAGR from 2026 to 2036, making it the fastest-growing country market profiled by Fact.MR.

The FDA has established regulatory pathways for AI-enabled medical devices and continues to develop guidance addressing lifecycle management, marketing submissions, and AI-related considerations. The agency also maintains a public list of AI-enabled medical devices authorized for marketing in the United States.

Germany follows at 14.1% CAGR, supported by its regulated medical-device environment and institutional experience with digital health products.

The United Kingdom is projected to grow at 13.7% CAGR, while Japan is forecast at 13.2%. Canada follows at 12.8%, France at 12.3%, and Australia at 11.8% through 2036.

Competitive Landscape

Key companies identified by Fact.MR include Siemens Healthineers AG, GE HealthCare Technologies Inc., Koninklijke Philips N.V., Medtronic plc, Boston Scientific Corporation, Abbott Laboratories, Oracle Health, Epic Systems Corporation, Veradigm LLC, and Aidoc Medical Ltd.

Competition spans large medical-device and healthcare technology companies as well as specialist AI imaging providers.

Siemens Healthineers, GE HealthCare, and Philips have established positions across medical imaging and hospital technology. Medtronic, Boston Scientific, and Abbott participate in software-enabled diagnosis, monitoring, and treatment workflows.

Aidoc represents a more specialized medical-imaging software model, while Oracle Health, Epic, and Veradigm operate within broader clinical information environments.

The key competitive threshold is shifting toward clinical evidence and lifecycle governance. Suppliers must demonstrate not only what software can do, but how safely it performs within a defined medical purpose.

High Risk IMDRF Category III & IV SaMD Market Snapshot

2025 market value: USD 4.2 billion
2026 market value: USD 4.8 billion
2036 projected value: USD 16.9 billion
CAGR, 2026-2036: 13.4%
Absolute opportunity: USD 12.1 billion
Leading software type: Diagnostic Software, 42.0%
Leading application: Medical Imaging Diagnostics, 39.0%
Leading end user: Hospitals, 44.0%
Leading deployment model: Cloud-based Deployment, 56.0%
Leading risk classification: IMDRF Category III, 61.0%
Fastest-growing profiled country: United States, 14.6% CAGR

Unlock 360° insights for strategic decision making and investment planning: https://www.factmr.com/report/high-risk-imdrf-category-iii-and-iv-software-as-a-medical-device-market

Report Scope and Methodology

The Fact.MR study evaluates the high-risk IMDRF Category III & IV Software as a Medical Device market across software type, application, end user, deployment model, risk classification, and region.

Software types include diagnostic software, therapeutic software, monitoring software, and clinical workflow software. Applications cover medical imaging diagnostics, digital therapeutics, remote patient monitoring, and hospital workflow management.

The study also evaluates hospitals, specialty clinics, telehealth providers, and integrated delivery networks. Deployment models include cloud-based deployment, on-premises deployment, Software as a Service, API integration, and enterprise system integration.

Risk classification covers IMDRF Category III and IV alongside continuous monitoring and AI-enabled clinical software where the intended medical purpose meets the high-risk definition.

Fact.MR's assessment draws on 120+ sources, 35+ company portfolios, 25+ countries, and more than 20 industry interviews, combining primary research, regulatory analysis, market sizing, company assessment, country-level forecasting, and data validation.

Explore More Related Studies Published by Fact.MR Research:

Connective Tissue Disease Market- https://www.factmr.com/report/connective-tissue-disease-market

Laboratory Animal Medicine Market- https://www.factmr.com/report/laboratory-animal-medicine-market

Lifestyle Diseases Apps Market- https://www.factmr.com/report/lifestyle-diseases-apps-market

Longevity Wellness Pharmaceutical Market- https://www.factmr.com/report/longevity-wellness-pharmaceutical-market

Psychiatric Digital Biomarkers Market- https://www.factmr.com/report/psychiatric-digital-biomarkers-market

Disclosure

This release is based on Fact.MR syndicated research. Market figures represent estimates and forecasts available as of the publication date and may be revised as additional information becomes available.

- Contact Us -
11140 Rockville Pike, Suite 400, Rockville,
MD 20852, United States
Tel: +1 (628) 251-1583 | sales@factmr.com

About Fact.MR

Fact.MR is an initiative of Eminent Research and Advisory Services, providing market intelligence and syndicated research across healthcare, food and beverage, consumer goods, technology, industrial goods, and other sectors. The company operates from offices in Rockville, Maryland, United States, and Dublin, Ireland.

This release was published on openPR.